Patients with Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Status: open

A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizuman in Patients with Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Treatment for Melanoma

Contact Us Or call (251) 445-9834

Description

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Sponsors

This trial is sponsored by Hoffmann-La Roche.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.